# Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

> **NCT00606125** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Nexavar (Sorafenib, BAY43-9006)

## Key facts

- **NCT ID:** NCT00606125
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-07
- **Final completion:** 2009-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606125, "Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00606125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*